Meeting
2017 ASCO Annual Meeting
Predictive role of FAS for trabectedin in second lines of advanced soft tissue sarcoma (ASTS): A Spanish group for research on sarcoma (GEIS) study.
Authors
Javier Martin Broto
Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS), Seville, Spain
Javier Martin Broto , David Marcilla , Rafael Ramos , David Silva Moura , Ramiro Alvarez , Nieves Hernandez , Carolina Agra Pujol , Empar Mayordomo , Cleofe Romagosa , Silvia Bague , Eugenia Reguero , Julia Cruz , Francisco Javier Martin , Antonio Gutierrez , Josefina Cruz , Rosa Maria Alvarez Alvarez , Robert Diaz Beveridge , Claudia Maria Valverde Morales , Antonio Lopez-Pousa , Javier Martinez-Trufero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11071)
DOI
10.1200/JCO.2017.35.15_suppl.11071
Abstract #
11071
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2022 ASCO Annual Meeting
Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population.
First Author: Xi Guo
Poster
2022 ASCO Annual Meeting
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
First Author: Sujana Movva
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of decitabine in combination with gemcitabine in treatment of advanced soft tissue and bone sarcomas.
First Author: Varun Monga